combine@alvar.ug

CCR5 promoter variants among Ugandan HIV-1 elite and viremic controllers: a laboratory ‑ based cross ‑ sectional study

CCR5 promoter variants among Ugandan HIV-1 elite and viremic controllers: a laboratory ‑ based cross ‑ sectional study

Show simple record

dc.contributor.author Brian Nyiro
dc.contributor.author Sharon Bright Amanya
dc.contributor.author Rose Nabatanzi
dc.contributor.author Alice Bayiyana
dc.contributor.author Linda Igumba Kalazane
dc.contributor.author Francis Waswa
dc.contributor.author Eva Nabulime
dc.contributor.author Daniel Karara
dc.contributor.author Joel Kabali
dc.contributor.author Gerald Mboowa
dc.contributor.author Alex Kayongo
dc.contributor.author Immaculate Nankya
dc.contributor.author David Patrick Kateete
dc.contributor.author Obondo James Sande
dc.date.accessioned 2021-01-11T13:51:38Z
dc.date.available 2021-01-11T13:51:38Z
dc.date.issued 2020
dc.identifier.uri https://combine.alvar.ug/handle/1/49377
dc.description.abstract Abstract; Background Mechanisms for HIV control among HIV-1 elite and viremic-controllers are not fully understood. In Uganda, Studies have reported individuals who without Antiretroviral therapy have the inherent ability to control HIV progression to AIDS for a period of greater than 5 years. However, reasons for this phenotype are not understood. The study objective was to determine the distribution of CCR5 co-receptor on CD4+ T-cells and its associated promoter variants among HIV-1 elite and viremic-controllers. Methods We isolated CD4+T-cells from PBMCs using EasySep CD4+ T-cell negative selection kit, and stimulated them with anti-CD3 and anti-CD28 for 48 hours. To quantify CCR5 expression, we performed immune-phenotyping using flow cytometry. CCR5 promoter polymorphisms were determined through sanger sequencing. The Kruskal–Wallis and the Mann-Whitney test were used to compare differences in the percentages of CCR5+ CD4+ T-cells and the differences in CCR5 densities on CD4+ T-cells respectively. p values < 0.05 were considered significant. Results The percentage of CCR5+CD4+ T-cells was higher among the non-controllers compared to the controllers although, the difference was not statistically significant; elite and viremic-controllers (p=0.9173), viremic and non-controllers (0.0702), elite and non-controllers (0.6010). Of significance was the CCR5 densities on CD4+ T-cells, which were significantly higher among non-controllers relative to the controllers; elite and viremic-controllers (p=3048), viremic and non-controllers (P=0.0312), elite and non-controllers (P=0.0210) From the sequence analysis, the rs1799987A>G mutation was found among elite (71%) and viremic-controllers (61%), while the -2459A/A and rs41469351C>T mutation were among the non-controllers (57%). This study also identified two novel mutations 1070T>G and 785A>G among the elite controllers (14.3%). Conclusion Rs1799987 SNP highly detected among the elite and viremic controllers may be associated with reduced CCR5 densities on CD4+ T-cells while higher frequency of -2459 A/A and rs41469351 SNP among non-controllers may be associated with increased CCR5 densities on CD4+ T-cells. Thus Rs1799987 SNP may be responsible for the delayed HIV progression among elite and viremic controllers, while -2459A/A and rs41469351 SNP may be responsible for the rapid progression of HIV among non-controllers. In vitro studies are needed to study the effect of the two novel mutations 1070T>G and 785A>G among elite-controllers.
dc.publisher Research Square
dc.title CCR5 promoter variants among Ugandan HIV-1 elite and viremic controllers: a laboratory ‑ based cross ‑ sectional study
dc.type Preprint
dc.identifier.doi 10.21203/rs.3.rs-47544/v1
dc.identifier.lens 000-589-845-584-058


This record appears in the collections of the following institution(s)

Show simple record

Search Entire Database


Browse

My Account